Sorry, this activity has expired and is no longer available for CME credit. You may still enjoy the program.
CME Information
Provider Statement
This continuing medical education activity is provided by 
.
Support Statement
This activity is supported by independent medical education grants from Genentech, Inc.; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals, Inc.
Target Audience
The intended audience for this educational series is retina specialists and other health care professionals involved in the management of patients with retinal diseases.
Learning Objectives
Upon successful completion of this publication series, participants should be better able to:
- Review recent innovations in imaging for the diagnosis and monitoring of retinal diseases.
- Evaluate new technology and imaging techniques used to monitor the treatment of patients with retinal diseases.
- Assess the evidence on safety and efficacy to optimize the use of conventional, new, and emerging medical treatments for retinal diseases.
- Evaluate new technology, devices, and techniques that may improve outcomes in patients undergoing vitreoretinal surgery.
Chief Medical Editor
Rishi P. Singh, MD
Staff Physician, Cole Eye Institute
Medical Director, Clinical Systems Office
Cleveland Clinic
Associate Professor of Ophthalmology
Case Western Reserve University
Cleveland, OH
Editorial Board
David Eichenbaum, MD
Director of Research
Retina Vitreous Associates of Florida
Collaborative Associate Professor
Morsani College of Medicine
University of South Florida
St. Petersburg, FL
Carl D. Regillo, MD, FACS
Director, Wills Eye Retina Service
Professor of Ophthalmology
Thomas Jefferson University
Mid Atlantic Retina
Philadelphia, PA
Charles C. Wykoff, MD, PhD
Retina Consultants of Houston
Retina Consultants of America
Blanton Eye Institute
Houston Methodist Hospital
Houston, TX
Faculty Contributors
Nika Bagheri, MD
California Retina Consultants and Research Foundation
Santa Barbara, CA
Anita Barikian, MD
Medical Retina Instructor, Bascom Palmer Eye Institute
Miami, Florida
Andrew X. Chen, BSE
Case Western Reserve University School of Medicine
Cleveland, Ohio
Thais F. Conti, MD
Center for Ophthalmic Bioinformatics, Cole Eye Institute
Cleveland Clinic Foundation
Cleveland, OH
Jorge A. Fortun, MD
Associate Professor of Ophthalmology
Bascom Palmer Eye Institute
Miami, FL
Tyler E. Greenlee, DO
Research Fellow
Cleveland Clinic Foundation
Cleveland, OH
Andrew A. Moshfeghi, MD, MBA
Director, Vitreoretinal Surgery Fellowship
Director, Clinical Trials Unit
Associate Professor of Clinical Ophthalmology
University of Southern California Roski Eye Institute, Keck School of Medicine
Los Angeles, CA
Dante J. Pieramici, MD
Director, California Retina Research Foundation
Partner, California Retina Consultants
Santa Barbara, CA
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which is defined as answering ALL the posttest questions and includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning requirements for the American Board of Ophthalmology’s Maintenance of Certification (ABO MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting MOC credit. Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn MOC credits equivalent to the amount of CME credits claimed for the activity. The CME activity provider will submit learner completion information to the ACCME for the purpose of granting ABO MOC credits within 30 days of activity completion.
This enduring material is approved for 1 year from the date of original release, July 1, 2020, through July 1, 2021.
How to Participate in This Activity and Obtain CME Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, read the articles, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.
Chief Medical Editor, Editorial Board, and Faculty Contributors report the following relationship(s)
Nika Bagheri, MD
Consulting Fee: Genentech
Anita Barikian, MD
No relevant financial relationships to disclose.
Andrew X. Chen, BSE
No relevant financial relationships to disclose.
Thais F. Conti, MD
No relevant financial relationships to disclose.
David Eichenbaum MD
Consulting Fee: Alimera, Allergan, Clearside, Dutch Ophthalmic, EyePoint, Genentech, Gyroscope, Kodiak, Notal Vision, Novartis, RecensMedical, Regeneron
Speakers Bureau: Allergan, Dutch Ophthalmic, Genentech, Novartis
Contracted Research: Alimera, Allergan, Chengdu Kanghong, Clearside, Genentech, Gyroscope, Kodiak, Mylan, NGM Biopharmaceuticals, Ophthotech/Iveric Bio
Ownership Interest: Boston Image Reading Center, Clearside, Hemera Biopharmaceuticals, Network Eye
Jorge A. Fortun, MD
Consulting Fee: Alimera, Allergan, Novartis
Contracted Research: Genentech
Tyler E. Greenlee, DO
No relevant financial relationships to disclose.
Andrew A. Moshfeghi, MD, MBA
Consulting Fee: Alimera, Allegro, Allergan, Clearside, EyePoint, Genentech, Graybug, Novartis, Pr3vent, Regeneron, Regenxbio
Contracted Research: Genentech, Novartis, Regeneron
Ownership Interest: OptiSTENT, Pr3vent
Dante J. Pieramici, MD
Consulting Fee: Adverum, Allegro, Gemini, Genentech, Novartis, Regeneron, Regenxbio
Contracted Research: Adverum, Apellis, Gemini, Genentech, Greybug Vision, Ionis, Kodiak, Novartis, Opthea, Regeneron, Regenxbio, Stealth BioTherapeutics
Ownership Interest: Gemini
Carl D. Regillo, MD, FACS
Consulting Fee: Adverum, Allergan, Chengdu Kanghong, Genentech, Graybug, Kodiak, Merck, Notal Vision, Novartis, Takeda
Contracted Research: Adverum, Allergan, Chengdu Kanghong, Genentech, Graybug, Kodiak, Notal Vision, Novartis, Regeneron, Regenxbio
Rishi P. Singh, MD
Consulting Fee: Alcon, Bausch + Lomb, Genentech, Novartis, Regeneron, Zeiss
Contracted Research: Aerie, Apellis, Graybug
Charles C. Wykoff, MD, PhD
Consulting Fee: Acucela, Adverum, Alimera, Allegro, Allergan, Apellis, Bayer, Chengdu Kanghong, Clearside, DORC, EyePoint, Genentech/Roche, Iveric Bio, Kodiak, Merck, Neurotech, Novartis, ONL Therapeutics, Oxurion, PolyPhotonix, Recens Medical, Regeneron, Regenxbio
Speakers Bureau: Regeneron
Contracted Research: Adverum, Aerie, Allergan, Apellis, Chengdu Kanghong, Clearside, Gemini Therapeutics, Genentech/Roche, Graybug Vision, Ionis Pharmaceuticals, Iveric Bio, Kodiak, Neurotech, Novartis, Opthea, Optos, Outlook Therapeutics, Recens Medical, Regeneron, Regenxbio, Samsung, Santen
Reviewer reports the following relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com